JP Morgan Maintains Neutral on Biogen, Lowers Price Target to $240
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Chris Schott has maintained a Neutral rating on Biogen (NASDAQ:BIIB) and reduced the price target from $270 to $240. This adjustment reflects a more cautious outlook on the company's future performance.
April 11, 2024 | 12:49 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
JP Morgan's analyst Chris Schott has maintained a Neutral rating on Biogen but lowered the price target from $270 to $240, indicating a more conservative view on the company's valuation and future performance.
The reduction in Biogen's price target by JP Morgan suggests a less optimistic outlook on the company's future earnings and growth potential. This could lead to a negative short-term impact on the stock price as investors adjust their expectations based on this new analyst assessment.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100